Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Somehow...got bounceback from MSTX and DARA at the close and ended up $54 in the green. With the last few days, I'll take it :)
Down 2.22% today in my 5 holdings. Not the end of the world. So will be sitting and waiting for the green colors to start appearing on the screen. I'll adjust the 'tint' of the monitor if I have too.
Looks like you're still up on the remaining half you sold correct? Even after the CRL.
DARA $.58 - Down 10% after financials and no mention of ODD update. They re-submitted ODD paperwork in November and typically an answer is given in 90 days from what I've read. Although the original submission was a year or so ago. So a verrrryyyyy long delay so far.
-------------------
Provided U.S. Food and Drug Administration (FDA), on November 19, 2013, with additional information requested in support of DARA's request for orphan drug designation for the Company's Phase 2 development asset, KRN5500, for the treatment of painful, treatment-refractory, chronic chemotherapy-induced peripheral neuropathy ("CCIPN").
-------------------
Will be meeting on reverse stock split on Feb 5 and the investor conference/presentation is on Monday.
I am holding for a little while more. Will see what happens in meeting tomorrow and into next week. Am in no hurry to sell, so will wait it out for now.
DARA - Reports 2013 Fourth Quarter and Full Year Financial Results and Commercial Business Update
link: http://finance.yahoo.com/news/dara-reports-2013-fourth-quarter-121000608.html
RALEIGH, NC--(Marketwired - February 04, 2014) - DARA BioSciences, Inc. (DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, announced today its financial results for the fourth quarter and full year ended December 31, 2013. The Company also provided a business update on its fourth quarter 2013 operational and commercial highlights.
Fourth Quarter 2013 Financial Snapshot
For the year ended December 31, 2013, DARA reported a net loss attributable to controlling interest of ($9,965,014), or ($0.39) per share as compared to a net loss attributable to controlling interest of ($7,311,033), or ($0.60) per share for the year ended December 31, 2012. The increase in loss was primarily a result of the costs incurred in the establishment of a sales and marketing infrastructure to support the promotion of the Company's oncology and oncology supportive care products as well as a related increase in general and administrative expenses as the Company continued its transition from what had been solely a research and development company. As of December 31, 2013, cash and cash equivalents and available for sale investments totaled approximately $3,425,543.
DARA believes that its currently available funds, together with projected sales of Soltamox®, (tamoxifen citrate) oral liquid solution, Gelclair®, an FDA-approved bioadherent oral rinse gel for treating the painful symptoms of oral mucositis (OM), Bionect®, (hyaluronic acid sodium salt, 0.2%) a topical treatment for skin irritation and burns associated with radiation therapy and the Mission Pharmacal products, Ferralet® 90 (for anemia), BINOSTO® (alendronate sodium effervescent tablet indicated for the treatment of osteoporosis), and Aquoral® (for cancer-related dry mouth), will enable the Company to fund its planned operations and to meet its obligations through the first quarter of 2014.
On December 23, 2013, DARA filed an S-1 Registration Statement with the U.S. Securities and Exchange Commission (SEC) announcing its intention to raise additional capital to extend its cash runway to fund operations to execute on its business plan.
David J. Drutz, MD, DARA's Chief Executive Officer and Chief Medical Officer, stated, "We are seeing encouraging sales performance in the fourth quarter based on our refined commercial strategy announced in the second quarter of 2013. The focus has been placed on increasing our share of voice targeting high-prescribing oncology practitioners."
The Company expanded its sales force and complemented its synergistic oncology supportive care product portfolio through a strategic partnership with Mission Pharmacal and its subsidiary, Alamo Pharma Services.
As of January 2, the Company's new commercial force provided through Alamo has been hired, professionally trained and is in the field selling the Company's synergistic product portfolio to the highest prescribing oncology offices nationwide.
Dr. Drutz continued, "Further, an important driver of our strategy is to continue to work closely with oncology market leaders in pursuit of contracts that will optimize the utilization of our product portfolio, similar to our recent agreements with Memorial Sloan Kettering Cancer Center and RainTree Oncology. Finally, we intend to further expand our oncology supportive care product portfolio and are actively looking to in-license or acquire additional products. I believe executing on these key initiatives will have a significant, positive impact on DARA's performance in 2014."
FOURTH QUARTER 2013 OPERATIONAL HIGHLIGHTS AND RECENT KEY EVENTS
The Company made significant progress during the fourth quarter of 2013 in executing its strategy as well as expanding the commercial opportunity for its flagship oncology and oncology supportive care products. The Company:
Continued execution of refined commercial strategy, implemented at the end of Q2 2013, focused on increasing sales call frequency to targeted high volume customers, resulting in increased aggregate Soltamox and Gelclair revenues of approximately 31 percent over Q3 2013;
Entered into an agreement to increase the Company's national field sales organization from five to 20 representatives, through Alamo Pharma Services, an experienced and successful contract sales organization, to continue to drive product momentum and provide the necessary scope and coverage of high prescribing oncologists maximizing the potential of DARA's product portfolio;
Signed a shared sales force agreement expanding DARA's presence in oncology supportive care with Mission Pharmacal for the Alamo sales team to carry DARA's products as well as three Mission Pharmacal products : Ferralet 90, BINOSTO, and Aquoral;
Through the Company's partnership with Alamo, interviewed, hired and trained 20 sales representatives for nationwide field force deployment on January 2, 2014;
Completed CAPTURE (Compliance and Preference for Tamoxifen Registry); 17 leading oncology centers enrolling a total of 626 women who had been prescribed and were taking tamoxifen therapy for breast cancer completed the CAPTURE survey, providing investigators with valuable insight into adherence to prescribed tamoxifen treatment; patient preference for a liquid formulation of tamoxifen; and prevalence of difficulties in swallowing among breast cancer patients taking tamoxifen tablets. Results expected to be reported in the first quarter of 2014;
Submitted CAPTURE clinical abstract to National Comprehensive Cancer Network® (NCCN) for presentation and anticipate presenting these data at upcoming oncology conferences in 2014;
Signed agreement with Memorial Sloan Kettering, a well-recognized worldwide, leading cancer institution for the exclusive placement of Gelclair on its formulary;
Signed a pharmacy supply agreement with RainTree Oncology Services, the nation's leading community oncology alliance, for both Gelclair and Soltamox to be accessible to RainTree's Nationwide Oncology Membership; and
Provided U.S. Food and Drug Administration (FDA), on November 19, 2013, with additional information requested in support of DARA's request for orphan drug designation for the Company's Phase 2 development asset, KRN5500, for the treatment of painful, treatment-refractory, chronic chemotherapy-induced peripheral neuropathy ("CCIPN").
Dr. Drutz concluded, "Oncology supportive care remains a unique market niche and growth opportunity for DARA, and we believe our product portfolio meaningfully addresses unmet needs for patients suffering from cancer and the side effects of their treatments. We are singularly focused on oncology/supportive care, and we believe we provide a comprehensive offering of these types of products in the market place. Our goal is to be the leader in the oncology/supportive care market with a comprehensive and growing portfolio of synergistic products to offer physicians and their patients. DARA has made substantial progress over the past two quarters. The recent expansion of our sales organization, marketing campaigns and product portfolio supports this vision and sets the stage for an exciting 2014 for DARA and our shareholders."
A summary of key financial highlights for the three and twelve months ended December 31, 2013 and 2012 is as follows ($ in thousands):
For the three
months ended
December 31,
2013 For the three
months ended
December 31,
2012 For the year ended
December 31,
2013 For the year ended
December 31,
2012
Net Product Revenues $182.3 $53.6 $419.3 $53.6
Costs and Expenses 2,587.9 3,618.8 10,908.7 9,690.7
Net Loss Attributed to Controlling Interest
(2,354.1 )
(1,871.3 )
(9,965.0 )
(7,311.0 )
As of December 31, 2013
As of December 31, 2012
Cash and Cash Equivalents
$3,425.5
$6,496.5
Current Assets 3,888.6 7,044.8
Current Liabilities 1,675.0 2,038.9
Working Capital 2,213.6 5,005.9
Fantastic Sheep!!! Thanks for sharing.
We all have trades like CPRX that we get into even though that little voice might be saying "hey - it was a good play before, but things changed, so maybe hold off for now"... and then we get into it anyway. The psychology of all of this is amazing.
I did the AEZS and DRRX is December and got 15% or so off each.
You waiting for the market to stabilize a bit before entering some more?
Again - Congrats!
IPCI - Doing well, although IMO market is pulling it / holding it down.
Am holding my 1,000 shares at the moment. Daily chart shows lot of room to roam. So, may give it some time. Depends upon market.
IPCI : NEWS - Payment Received
http://finance.yahoo.com/news/intellipharmaceutics-receives-3-1-million-120000166.html
First Profit-Share Payment on 15 and 30 mg Generic Focalin XR(R) Sales
TORONTO, Feb. 3, 2014 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced the receipt of approximately $3.1 million as its first payment relating to commercial sales of dexmethylphenidate hydrochloride extended-release capsules by its licensee Par Pharmaceutical, Inc. ("Par"). This represents the Company's share of profits for the 15 and 30 mg strengths of the drug product for the period commencing with the first commercial sales of those strengths on November 19, 2013 and ending December 31, 2013 under its License and Commercialization Agreement with Par. Future profit-share payments are expected on a quarterly basis, although the amounts of any such payments cannot now be determined and may vary significantly from time-to-time. All dollar amounts referenced herein are in United States dollars unless otherwise noted.
As the first-filer for the drug product in the 15 mg strength, the Company currently has 180 days of exclusivity of generic sales for that strength from the November 19, 2013 date of launch in the United States by Par. In addition, Intellipharmaceutics has the potential to receive its share of the profits on the 5, 10, 20 and 40 mg strengths which were also tentatively approved by the United States Food and Drug Administration ("FDA"), subject to the right of another party or parties to 180 days of generic exclusivity from the date of first launch of such strengths of the drug product by such parties. The Company currently believes Par intends to launch these strengths immediately upon the expiry of those exclusivity periods and upon the anticipated final approvals from the FDA at those times, but there can be no assurance as to if or when any such approvals or launches will occur.
At the present time, publicly available records of the FDA show that only four entities, including the Company, have received approvals or tentative approvals to market one or more generic strengths of this drug product. Further, the Company believes that only three of those entities, including the Company, have commenced sales of one or more generic strengths of the drug product. Dr. Isa Odidi, CEO and co-founder of the Company, stated, "We believe that the number of competitors tentatively approved or in the market at this time is an indication that our drug delivery technologies and competence are robust and well-adapted to the formulation of difficult-to-replicate generic drug products."
Intellipharmaceutics disclaims any intention and has no obligation or responsibility, except as required by law, to make, update or revise any statements regarding any future profit-share payments under its agreement with Par.
Thanks. There's been a lot of athletes who started out ok and then were never heard from again. I'm hoping not to be another Joe Charboneau. Time will Tell.
I don't use Trade King so can't tell you specifically, but I did find this page which might point you in the right direction...
link : https://www.tradeking.com/trading/accounts/gain-loss
As far as easily creating screen shots, if you use Windows, then the "Snipping Tool" is awesome for fast screen shots. Truthfully, I never knew the tool existed until I read this post from $$$eeker, with great instructions on how to add a screenshot image to your posts.
Easy(ish) Screenshot Snipping Info link : http://investorshub.advfn.com/boards/read_msg.aspx?message_id=95136594&txt2find=snipping
OT: Seahawks 27 - Broncos 20
(I don't care who wins - Superbowl means NCAA Basketball tourney is near and Baseball after that).
Thanks. I think doing postings like this will help to keep me focused and leaves me accountable for my trades. I was a lurker in these boards off and on for years, and am hoping to turn the lurking into success. The only way how, is to keep sharing ideas and learning from all of you. So far, so good, but its a constant learning process for me.
Looking forward to seeing how you did, and also maybe one or two "why you entered into a trade, and why you decided to exit" also. We can't do them all, but maybe highlight one or two. If I remember correctly, I believe you mentioned that you lightened up on some holdings to wait and see how the markets shake out. Even hearing about that is helpful. Thanks.
Good. Did some house cleaning and moved into RGDX.
December: Gain of $3,815.90
January: Gain of $3,999.13
Should have been double that in Jan, as I had the gains, but again, I'm wasn't aggressive enough. I definitely won't be complacent going forward. Sold both CPRX and CBMX because I had small positions in them and wanted to enter other trades.
Goal for February is $6,052.
I cleaned house of ETRM and ACHN. My trades are normally for 1 day to 2 weeks, or as long as the pattern holds. I didn't follow my rules, so time to get back into trades that do follow my charts and rules. ETRM may still do fine, but the delayed ADCOM is a worry to me and also have seen some talks of offerings. I need to look into that for the future to see when their last offering was and how much $$$ they have.
RGDX: Added 7,000 shares
KIPS: Holding 5,000
DARA: Holding 10,500
MSTX: Holding 7,700
IPCI: Holding 1,000
Watching APPY and IDN, may add early next week. Holding KIPS, looking just fine. Will look to exit IPCI this week.
OPTIONS
I'll transfer some money into my other account and play some options from there soon. I'd like to get some CHTP calls, as well as take out some options on the SDS,QID,TZA,IBB, etc. as hedges on the account.
Covered Calls. Am also looking into trying covered calls as a hedge also.
PORTFOLIO
I also want to play only 5 stocks maximum if possible. More than that and I think its too hard for me to watch close enough not to make mistakes. I also want to add non-bios, only because having nothing but bios is bad for when that sector cycling. Diversify.
Yesterday is gone, Monday will be here soon. Learn and earn.
Am keeping my mouth shut next time.
RGDX - Am in for 7,000 shares at $1.39. BOL to all.
Probably yes. btw ...MSTX says its want to boogie right now.
ETRM - $2.10 I'm out
-$301 loss in total for it. Was up $500 or so. Should have banked some or all. My mistake.
Saw SPX doing a little breakout pop, so got another 1,800 RGDX at 1.39. Will look to add more or maybe APPY still. Also still watching IDN as that chart looks good to me.
IPCI - Earnings Email Reply
I just received this response from an email sent to IPCI Investor Relations...
----------------------------
Ned "Hi, Could you please tell me the date and time that earnings will be released? I've seen 1/30/14 on earningswhisper.com, 1/31/14 on nasdaq and others, and TD ameritrade shows the week of Feb 4th, so its confusing."
and the reply...
Smith, Kirin ksmith@proactivecapital.com
11:52 AM (41 minutes ago)
Thanks for your inquiry. The Company has not announced an exact date so those sites you reference are estimating probably based on when the company reported last year.
Feel free to call with any other questions.
Best,
Kirin
I agree with you. Have my finger on the trigger at the moment, as IMO RGDX is itching to pop. Just needs some volume. Whether that's today or next week. Dunno.
Only thing to pull it down IMO to the 50DMA, I think is a market dump. Am waiting for ETRM to do that final pop right now, so I can get out of it possibly at 2.18 or 2.25, and into RGDX then.
I'm buying Pepsi stock then. They own Doritos, Cheetos and Frito Lay I think. Munchees will be needed.
RGDX : $1.39 - Bought 3,000 shares. May buy another 3,000 soon. Was waiting to see if she'd dip to the 1.32 50DMA in this sea of red. But bought a starter.
ACHN - Sold my 1,700 shares for a $174.30 profit, instead of the $1,700 profit i had. Dumbass. I see it moving up from here, but am going into RGDX, GSS, or APPY and feel great about RGDX and APPY. With the market down, will see if I can catch some of their wabbits running loose.
IBB - Biotech Seasonality Charts
I wanted to post this the other day, but didn't have the chance. This is the reason why I thought it'd be a good idea to buy some Puts for the IBB (right before the market dipped last week). I need to add funds to a different account that I have to do options. I'll do so soon.
Take a look at the slope of the IBB in January. Too good to be true. And it was, and it fell. The slope was amazing compared to the last 3 years.
If you use the link below, you can also select the 3 little buttons in the lower left of the chart on the stockcharts site, and it will show the last few years of the IBB and how its done, on a month to month basis, and other things. You can also compare it to another symbol.
From 2009 to 2013, the IBB closed the month higher 80% of the time in FEB, 100% in MAR, and 80% in APR. JUN was 40% and AUG 20% of the time it closed the month higher than it began. Fun stuff to think about.
Stock Seasonality Chart: link : http://stockcharts.com/freecharts/seasonality.php?symbol=ibb&compare=
Am looking to get into both APPY and RGDX tomorrow.
Was thinking IPCI earnings were this afternoon, so was looking to sell in after-hours, but nooooooo. So, not sure when it is (am going to send them an email now to find out). I only have 1,000 shares though.
ACHN - 1,700 - Looks to be turning up again and a decent play, but I'm itching for better gains with RGDX and APPY, so may re-vist ACHN later. Get out with a small gain.
DARA - 10,500 - Holding
ETRM - Sold 500 shares today. Have 1,500 left. Will probably sell for my biggest loss to date (-$500), but again...thinking there's better plays and no news from them about the ADCOM, etc. Not sure what's going on. Plus if I sell, it increases your odds of them coming out with news :)
IPCI - 1,000 - Holding until after earnings unless it runs up good tomorrow, and will lock in $.
KIPS - 5,000 - Holding
MSTX - 7,700 - Holding
Was a nice finish today in SPX, above 1792. So, hopefully it'll be strong tomorrow. In a perfect world a few holdings would pop so I can move to 50% cash. Still not completely bought into the rally here, but will go with it for now.
Am totally trusting now how I play the charts. If I would have done so, life would be so much easier and I would have banked better $. But "The past is for cowards and losers" says Coach Ditka.
So am reminding myself over and over to stay focused, and be aggressive. Being strict with my rules and aggressive will win.
We did well with the picks, but then again bios were running super hot. So LOCK IN GAINS! is the key.
Yup. Agree totally. It's about to razzle dazzle if the markets hold up.
Ok. I thought I originally saw the date of the 31st, but have seen the 30th in a few places too, so I guess we'll find out tomorrow. Thanks.
FYI: My TD Ameritrade account shows:
The next earnings announcement from IPCI is expected the week of February 4, 2014.
So, I have no idea really.
Yeah, I was hoping for that double bottom and a pop so I could exit out of this and into RGDX or APPY. Will look to do so tomorrow perhaps.
IPCI - I haven't seen any earnings info yet. Seen anything about it?
Dara fizzled out...fffffzzzzzzzzzzzzzz. I was going to sell 1/2 at 80. Juuuuust missed it with my snoozing finger.
DARA $.79 Pre-market : DARA Moving in Premarket, this time with Volume too. I believe this is what is making it move:
link here for full article : http://finance.yahoo.com/news/dara-biosciences-signs-pharmacy-supply-130500006.html
DARA BioSciences, Inc. (DARA), an oncology supportive care specialty pharmaceutical company dedicated to providing healthcare professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatments, announced that it has signed a pharmacy supply agreement with RainTree Oncology Services. This agreement is for both Gelclair®, an FDA-approved bioadherent oral rinse gel for treating the painful symptoms of oral mucositis (OM), and Soltamox® (tamoxifen citrate) oral liquid solution, to be accessible to RainTree's Nationwide Oncology Membership.
As the nation's leading community oncology alliance, RainTree Oncology Services assists its member practices in providing effective treatments to oncology patients, while developing commercial relationships that accelerate innovative oncology treatments and payer arrangements optimizing oncology patient care and advancing the practice of oncology. This agreement with RainTree Oncology Services gives RainTree member practices access to DARA's products. RainTree and DARA will work to provide both products to the RainTree nationwide oncology membership, many of which have in-house pharmaceutical dispensing services.
"We believe Gelclair and Soltamox address important therapeutic needs for thousands of patients treated by RainTree member practices and present a new opportunity to service the needs of patients suffering from cancer and cancer treatment side effects directly at the point of care. We are excited with the opportunity to offer product access to RainTree's member practices for both Soltamox and Gelclair and the opportunity to collaborate with them on this front. We view these types of strategic relationships as an integral component to our commercial success," stated David J. Drutz, M.D., DARA BioSciences' Chief Executive Officer and Chief Medical Officer.
Christopher Clement, DARA's President and Chief Operating Officer, commented, "Following the recent signing of our two-year exclusive agreement with Memorial Sloan Kettering for formulary access for Gelclair, we continue to work closely with other oncology market leaders in pursuit of additional agreements to optimize the utilization of our product portfolio. These relationships, in concert with the launch of our newly instituted 20 person national sales force earlier this month, are important drivers for what we anticipate to be an exciting 2014 for DARA."
OT: Finish each day & be done with it. You have done what you could. Learn from it; tomorrow is a new day.
-Ralph Waldo Emerson
--------------------------
I thought today was a new day? You mean its tomorrow?
Yup, was watching for a good finish, but more of a limping across the finish line was what it was.
RGDX did hold up well today though. Perhaps it will be the turnaround day for it hopefully. If I had some money freed up, I'd be in it now.
The Day's not done yet Smurf. Let's see how we move from here.
They'll be good days, and bad days. We have to plan for all and trade with them in mind.
Stay focused.
No real volume, just two small trades of 900, so not a real indicator. But...better than nothing.
Just something to think about, and look for.
Then again, with the way the futures have tanked from S&P up 10 late last night to down - 13 right now, looks like a down day at the moment, so take that in mind.
Could be a very volatile day with the Fed meeting, etc. Not looking good right now though. So, I may lighten up on some holdings. Will have to see how it goes.
Charts don't always play in crazy days.
IDN - $.506 - Came up in one of my scans.
Recently closed an offer at $.45 on Jan 14th
Link: http://finance.yahoo.com/news/intellicheck-mobilisa-announces-closing-public-163700719.html
Intellicheck Mobilisa, Inc. (NYSE MKT: IDN), a global leader in identity solutions and wireless security systems, today announced the closing of a previously announced underwritten public offering of 7,780,000 shares of its common stock, and the full exercise of the over-allotment option to purchase 1,167,000 additional shares, offered at a price to the public of $0.45 per share. The total gross proceeds to Intellicheck Mobilisa from this offering are approximately $4,026,000 before deducting the underwriting discount and other estimated offering expenses payable by Intellicheck Mobilisa.
Volume picking up recently.
No LONG TERM debt according to Yahoo Finance.
Jan 21st, obtains US patent
Jan 23rd, releases ID scanning product for Mexican Licenses - Link: http://finance.yahoo.com/news/intellicheck-mobilisa-releases-id-scanning-123000217.html
Is on watch for me.
RGDX : $1.38 - Two volume spikes on the 15 Min chart to end the day. The daily chart shows the price nearing the 50 DMA at $1.32. IMO RGDX is looking very good to make a turnaround tomorrow, or very near future.
If it falls to 50 DMA at $1.32, I'd expect VERY GOOD support. I am looking to free up money if possible to enter RGDX. Otherwise will watch and let my hands play out.
OT: Was an "Ehhhh" day overall, lil bit under even.
Had some like IPCI finally rebound while my two others like MSTX and DARA dragged their feet. Dara had very low volume today.
Watched the SPX play peekabo with 1792ish. We'll see what tomorrow knows...
"Where he who waits for the day's riches will be lost
In the whispery town
Where the river flows
Tomorrow never knows"
Bruce Springsteen (Tomorrow Never Knows)
Jan 27, 2014 : Wells Fargo reports 5.34% passive stake in EnteroMedics
Flyonthewall.com mention
link: http://www.theflyonthewall.com/permalinks/entry.php/ETRMid1952152/ETRM-Wells-Fargo-reports--passive-stake-in-EnteroMedics-